BCTC
- Product Name
- BCTC
- CAS No.
- 393514-24-4
- Chemical Name
- BCTC
- Synonyms
- BCTC;BCTC, 10 mM in DMSO;BCTC, inhibitor of TRPV1;N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide;4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide;1-Piperazinecarboxamide, 4-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-;4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-diMethylethyl)phenyl]-1-piperazinecarboxaMide (BCTC)
- CBNumber
- CB12122071
- Molecular Formula
- C20H25ClN4O
- Formula Weight
- 372.89
- MOL File
- 393514-24-4.mol
BCTC Property
- Melting point:
- 150-152℃
- Boiling point:
- 561.6±50.0 °C(Predicted)
- Density
- 1.229±0.06 g/cm3(Predicted)
- storage temp.
- Sealed in dry,Room Temperature
- solubility
- DMSO: >10mg/mL
- pka
- 13.95±0.70(Predicted)
- form
- powder
- color
- white to beige
- Sensitive
- Light Sensitive
- Stability:
- Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stord at -20°C for up to 2 months.
- InChI
- InChI=1S/C20H25ClN4O/c1-20(2,3)15-6-8-16(9-7-15)23-19(26)25-13-11-24(12-14-25)18-17(21)5-4-10-22-18/h4-10H,11-14H2,1-3H3,(H,23,26)
- InChIKey
- ROGUAPYLUCHQGK-UHFFFAOYSA-N
- SMILES
- N1(C(NC2=CC=C(C(C)(C)C)C=C2)=O)CCN(C2=NC=CC=C2Cl)CC1
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
- Precautionary statements
-
P270Do not eat, drink or smoke when using this product.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P330Rinse mouth.
P403Store in a well-ventilated place.
N-Bromosuccinimide Price
- Product number
- SML0355
- Product name
- BCTC
- Purity
- ≥98% (HPLC)
- Packaging
- 5mg
- Price
- $94.43
- Updated
- 2025/07/31
- Product number
- SML0355
- Product name
- BCTC
- Purity
- ≥98% (HPLC)
- Packaging
- 25mg
- Price
- $275
- Updated
- 2025/07/31
- Product number
- 10006309
- Product name
- BCTC
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $41
- Updated
- 2024/03/01
- Product number
- 10006309
- Product name
- BCTC
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $78
- Updated
- 2024/03/01
- Product number
- 10006309
- Product name
- BCTC
- Purity
- ≥98%
- Packaging
- 50mg
- Price
- $322
- Updated
- 2024/03/01
BCTC Chemical Properties,Usage,Production
Description
BCTC (393514-24-4) is a vanilloid receptor I (TRPV1) blocker, IC50 = 35 nM for capsaicin-induced and 6 nM for acid-induced TRPV1 activation. Displays analgesic activity in rat models of neuropathic pain. BCTC is orally active and cell permeable.
Uses
BCTC is a antagonists of TRPA1 and TRPV1, a non-selective cation channel gated by noxious heat, vanilloids and extracellular protons. BCTC inhibits both capsaicin and proton activation.
Definition
ChEBI: 1-piperazinecarboxamide, 4-(3-chloro-2-pyridinyl)-n-[4-(1,1-dimethylethyl)phenyl]- is a member of piperazines and a member of pyridines.
in vivo
BCTC (1-30 mg/kg; Oral gavage; Single dose) can inhibit inflammatory and neuropathic heat pain and mechanical hyperalgesia in Sprague-Dawley rats by targeting VR1, which has analgesic effect[2].
BCTC (10-100 mg/kg; Oral gavage, Twice daily for 4 weeks) improves the insulin resistance and systemic glucose and lipid metabolism, and increase insulin secretion in diabetic ob/ob mice[5].
| Animal Model: | Capsaicin-induced Sprague-Dawley rats model[2] |
| Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg |
| Administration: | Oral gavage (p.o.), Single dose. Before capsaicin (HY-10448) treatment (30 μg; intraplantar injection; Single dose) |
| Result: | Inhibited capsaicin-mediated thermal hyperalgesia in a dose-dependent manner. |
| Animal Model: | Freund’s complete adjuvant (FCA) Sprague-Dawley rats model[2] |
| Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg |
| Administration: | Oral gavage (p.o.), Single dose. After 100 % FAC treatment (50 μL; intraplantar injection; Single dose) |
| Result: | Significantly reduced FAC-induced inflammation-related thermal pain and mechanical hyperalgesia, and extended the inhibitory effect of mechanical hyperalgesia to 6 h at high doses (10 mg/kg, 30 mg/kg). |
| Animal Model: | Partial sciatic nerve ligation Sprague-Dawley rats model[2] |
| Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg |
| Administration: | Oral gavage (p.o.), Single dose. After partial sciatic nerve ligation. |
| Result: | Reduced post-operative abnormal tactile pain and mechanical hyperalgesia in a dose-dependent manner. |
| Animal Model: | Particularly strong insulin resistance and hyperinsulinemia ob/ob mice model[5] |
| Dosage: | 10 mg/kg, 30 mg/kg, 100 mg/kg |
| Administration: | Oral gavage (p.o.); Twice daily for 4 weeks |
| Result: | Reduced plasma triglyceride and glucose area under the curve (AUC) level. Decreased calcitonin gene-related peptide (CGRP) levels in a dose-dependent manner. |
storage
Room temperature
References
[1] KENNETH J VALENZANO. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.[J]. Journal of Pharmacology and Experimental Therapeutics, 2003, 306 1: 377-386. DOI:10.1124/jpet.102.045674
[2] JAMES D POMONIS. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain.[J]. Journal of Pharmacology and Experimental Therapeutics, 2003, 306 1: 387-393. DOI:10.1124/jpet.102.046268
BCTC Preparation Products And Raw materials
Raw materials
Preparation Products
BCTC Suppliers
- Tel
- --
- Fax
- --
- sales@carbosynth.com
- Country
- United Kingdom
- ProdList
- 6005
- Advantage
- 58
- Tel
- --
- Fax
- --
- customerservice@tocris.co.uk
- Country
- United Kingdom
- ProdList
- 5726
- Advantage
- 77
View Lastest Price from BCTC manufacturers
- Product
- BCTC 393514-24-4
- Price
- US $1.00/KG
- Min. Order
- 1KG
- Purity
- 98% HPLC
- Supply Ability
- 10t
- Release date
- 2019-12-20